Biocon Limited has informed the Exchange regarding a press release dated September 18, 2025, titled "Biocon Biologics Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases".
Biocon Limited has informed the Exchange regarding a press release dated September 18, 2025, titled "Biocon Biologics Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases".